Einzeltreffer — DigiBib

Cisplatin (cis-diamminedichloroplatinum II; CDDP) is a widely used cytostatic agent; however, it tends to promote kidney and liver disease, which are a major signs of drug-induced toxicity. Platinum compounds are often presented as alternative therapeutics and subsequently easily dispersed in the environment as contaminants. Due to the major roles of the liver and kidneys in removing toxic materials from the human body, we performed a comparative study of the amino acid profiles in chicken liver and kidneys before and after the application of CDDP and platinum nanoparticles (PtNPs-10 and PtNPs-40). The treatment of the liver with the selected drugs affected different amino acids; however, Leu and Arg were decreased after all treatments. The treatment of the kidneys with CDDP mostly affected Val; PtNPs-10 decreased Val, Ile and Thr; and PtNPs-40 affected only Pro. In addition, we tested the same drugs on two healthy cell lines, HaCaT and HEK-293, and ultimately explored the amino acid profiles in relation to the tricarboxylic acid cycle (TCA) and methionine cycle, which revealed that in both cell lines, there was a general increase in amino acid concentrations associated with changes in the concentrations of the metabolites of these cycles.

Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Titel:	Platinum-based drug-induced depletion of amino acids in the kidneys and liver.
Autor/in / Beteiligte Person:	Mitrevska, K ; Cernei, N ; Michalkova, H ; Rodrigo, MAM ; Sivak, L ; Heger, Z ; Zitka, O ; Kopel, P ; Adam, V ; Milosavljevic, V
Link:	Full Text Finder (Volltext)
Zeitschrift:	Frontiers in oncology, Jg. 12 (2022-09-21), S. 986045
Veröffentlichung:	[Lausanne : Frontiers Research Foundation], 2022
Medientyp:	academicJournal
ISSN:	2234-943X (print)
DOI:	10.3389/fonc.2022.986045
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Front Oncol] 2022 Sep 21; Vol. 12, pp. 986045. <i>Date of Electronic Publication: </i>2022 Sep 21 (<i>Print Publication: </i>2022). References: Support Care Cancer. 2019 Mar;27(3):1139-1147. (PMID: 30094732) ; Chem Soc Rev. 2017 Aug 14;46(16):4951-4975. (PMID: 28696452) ; Nanomaterials (Basel). 2018 Jun 01;8(6):. (PMID: 29865145) ; Int J Mol Sci. 2013 Oct 31;14(11):21629-46. (PMID: 24185911) ; Angew Chem Int Ed Engl. 2018 May 4;57(19):5389-5393. (PMID: 29569826) ; Biosci Biotechnol Biochem. 2013;77(8):1645-9. (PMID: 23924727) ; Int J Nanomedicine. 2019 Jul 22;14:5595-5609. (PMID: 31413565) ; Eur J Pharmacol. 2014 Oct 5;740:364-78. (PMID: 25058905) ; Toxicol Sci. 2006 Feb;89(2):515-23. (PMID: 16251482) ; J Control Release. 2007 Sep 26;122(2):135-40. (PMID: 17688966) ; Environ Sci Nano. 2017;4:. (PMID: 31080619) ; Int J Pharm. 2014 Oct 1;473(1-2):95-104. (PMID: 24997411) ; Kidney Int. 2006 Jun;69(12):2194-204. (PMID: 16672910) ; Cancers (Basel). 2020 Sep 10;12(9):. (PMID: 32927667) ; J Am Chem Soc. 2014 Apr 9;136(14):5181-4. (PMID: 24669930) ; ACS Nano. 2015 Oct 27;9(10):9626-37. (PMID: 26365698) ; Gen Physiol Biophys. 2017 Dec;36(5):513-520. (PMID: 29372684) ; J Mater Chem B. 2018 Apr 28;6(16):2474-2480. (PMID: 32254464) ; J Toxicol Environ Health A. 2022 Jan 2;85(1):29-42. (PMID: 34445936) ; J Phys Chem B. 2006 Nov 23;110(46):23052-9. (PMID: 17107143) ; PLoS One. 2017 Jul 12;12(7):e0180798. (PMID: 28704436) ; Front Mol Neurosci. 2017 May 31;10:174. (PMID: 28620280) ; Clin Cancer Res. 2007 Nov 1;13(21):6359-68. (PMID: 17975148) ; Nanomedicine (Lond). 2010 Jan;5(1):51-64. (PMID: 20025464) ; Oncol Rep. 2015 Feb;33(2):921-9. (PMID: 25434399) ; Int J Mol Sci. 2021 Aug 12;22(16):. (PMID: 34445378) ; Trends Biotechnol. 2014 Sep;32(9):448-55. (PMID: 25086728) ; Retin Cases Brief Rep. 2019 Summer;13(3):211-214. (PMID: 28333855) ; Int J Vitam Nutr Res. 1990;60(1):41-6. (PMID: 2387670) ; J Pharm Biomed Anal. 2017 Feb 20;135:20-30. (PMID: 27987392) ; Chem Rev. 2016 Mar 9;116(5):3436-86. (PMID: 26865551) ; Cancer Treat Rep. 1978 Dec;62(12):2125-6. (PMID: 751721) ; Toxicol Appl Pharmacol. 2011 Aug 15;255(1):94-102. (PMID: 21703291) ; Nutrients. 2018 Mar 22;10(4):. (PMID: 29565819) ; Onkologie. 2013;36(1-2):49-52. (PMID: 23429332) ; Oncologist. 2015 Apr;20(4):411-32. (PMID: 25765877) ; Chemother Res Pract. 2011;2011:843019. (PMID: 22312559) ; Annu Rev Nutr. 1984;4:409-54. (PMID: 6380539) ; Diabetes. 2014 Jul;63(7):2432-9. (PMID: 24677711) ; Cancer Chemother Pharmacol. 2017 Aug;80(2):317-332. (PMID: 28646338) ; J Exp Pharmacol. 2011 Apr 01;3:43-50. (PMID: 27186109) ; PLoS One. 2021 Feb 24;16(2):e0245383. (PMID: 33626044) ; Nanoscale. 2010 Dec;2(12):2607-13. (PMID: 20936240) ; Nanoscale Res Lett. 2013 May 24;8(1):251. (PMID: 23705751) ; Sci Rep. 2015 Jun 03;5:10881. (PMID: 26039249) ; Polymers (Basel). 2020 May 13;12(5):. (PMID: 32414187) ; Mol Cell Biochem. 2005 Oct;278(1-2):79-84. (PMID: 16180092) ; Sci Rep. 2019 Mar 21;9(1):4987. (PMID: 30899037) ; J Phys Chem B. 2006 Mar 23;110(11):5343-50. (PMID: 16539467) ; N Engl J Med. 1997 Jul 24;337(4):242-53. (PMID: 9227931) ; Br J Pharmacol. 2010 Feb;159(4):898-908. (PMID: 20067471) ; Free Radic Biol Med. 2020 Feb 20;148:128-139. (PMID: 31911150) ; Semin Nephrol. 2007 Nov;27(6):609-20. (PMID: 18061843) ; Int J Mol Sci. 2020 Jan 09;21(2):. (PMID: 31936679) ; Food Chem Toxicol. 2017 Jul;105:337-346. (PMID: 28465190) ; Environ Toxicol. 2020 Sep;35(9):930-941. (PMID: 32309901) ; Nanoscale. 2018 Jun 14;10(23):11176-11185. (PMID: 29873378) ; Cancer Biol Ther. 2021 Dec 2;22(10-12):579-586. (PMID: 34720054) ; Kidney Int. 2014 Apr;85(4):855-70. (PMID: 24304882) ; Cells. 2019 May 10;8(5):. (PMID: 31083475) ; Biomaterials. 2004 Jul;25(16):3259-66. (PMID: 14980420) ; J Control Release. 2016 Oct 28;240:332-348. (PMID: 26774224) ; Clin Nutr. 1984 Oct;3(3):153-62. (PMID: 16829451) ; Exp Anim. 2011;60(1):33-45. (PMID: 21325750) ; Eur J Pharmacol. 2017 Sep 15;811:125-128. (PMID: 28599874) ; J Phys Chem B. 2006 Dec 28;110(51):25916-25. (PMID: 17181240) ; Trends Biotechnol. 2017 Mar;35(3):257-264. (PMID: 27663778) ; IUBMB Life. 2020 Nov;72(11):2241-2259. (PMID: 32916028) ; Toxicol Appl Pharmacol. 1997 Oct;146(2):261-9. (PMID: 9344894) ; Cancer Lett. 2014 May 1;346(2):163-71. (PMID: 24462818) ; J Control Release. 2004 Sep 14;99(1):73-82. (PMID: 15342182) ; Ann Pharmacother. 1993 Apr;27(4):438-41. (PMID: 8477119) ; Metallomics. 2011 Nov;3(11):1244-52. (PMID: 21804981) ; Environ Sci Technol. 2016 Oct 4;50(19):10635-10643. (PMID: 27577171) ; J Proteome Res. 2017 Apr 7;16(4):1753-1762. (PMID: 28271897) ; Hear Res. 2007 Apr;226(1-2):140-56. (PMID: 17321087) ; Mater Sci Eng C Mater Biol Appl. 2016 Mar;60:569-578. (PMID: 26706565) ; Biomacromolecules. 2015 Feb 9;16(2):515-23. (PMID: 25543837) ; Sci Rep. 2017 Jul 3;7(1):4537. (PMID: 28674429) ; Metallomics. 2019 Oct 16;11(10):1716-1728. (PMID: 31497817) ; J Colloid Interface Sci. 2019 Mar 22;540:330-341. (PMID: 30660085) ; PLoS One. 2007 Aug 01;2(8):e690. (PMID: 17668068) Contributed Indexing: Keywords: TCA; amino acids; chicken embryo; methionine cycle; platinum nanoparticles; toxicity Entry Date(s): Date Created: 20221010 Latest Revision: 20221011 Update Code: 20240513 PubMed Central ID: PMC9535364

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Platinum-based drug-induced depletion of amino acids in the kidneys and liver.